Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GEN podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Add GEN to your Inbox FREE!

Subscribe today to our complimentary e-Newsletters and stay abreast of the latest biotech news and trends.


NEW PATH FOR TREATING AND PREVENTING EYE DISEASE

4/24/2008

- Interview with Dean Li, M.D.,Ph.D., Professor of Internal Medicine, University of Utah School of Medicine, and Research Scientist with the University's Program in Human Molecular Biology and Genetics

Researchers at the University of Utah School of Medicine and several other institutions report that two major eye diseases and leading causes of blindness can be treated in mice by drugs that activate a protein found in blood vessel cells. Damage from both diseases was prevented and even reversed when the protein, Robo4, was activated in mice models that simulate age-related macular degeneration (AMD) and diabetic retinopathy, according to a paper published March 16 in Nature Medicine online.


During this week's podcast, Dr. Dean Li, senior author of the study, discusses the key findings of the paper and the role of the Robo4 protein in relation to eye disease. The protein targets the VEGF signaling pathway and Dr. Li talks about how Robo4 differs from other molecules, including several FDA-approved drugs, that zero in on VEGF.


Dr. Li also provides details on the knockout mouse technology used in his team's research and explains why the study's ramifications could go well beyond eye diseases.
Dean Li, M.D., Ph.D., is a Cardiologist and Professor of Medicine at the University of Utah School of Medicine. His research laboratory is focused on understanding the pathogenesis of vascular disease.

Related content

GEN News Highlights

MORE RELATED GEN NEWS HIGHLIGHTS

Insight & Intelligence™

MORE RELATED INSIGHT & INTELLIGENCE™

GEN Articles

MORE RELATED GEN ARTICLES

GEN Podcasts

MORE RELATED GEN PODCASTS

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.
 

All fields are required
Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 

ADVERTISEMENT

GEN webinars

« View All Webinars »

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA on Biosimilars

How satisfied are you with progress toward bringing biosimilars to the U.S. market?

Suggest a Poll
« More »     « View Results »     « Poll Archive »